• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

复发性转移性低级别浆液性卵巢癌对BRAF抑制剂单药治疗的持久反应。

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.

作者信息

Sama Shashank, Rosqvist Sterling, Savage Talicia, Lomo Lesley, Sibbald Kiera, Straubhar Alli, Werner Theresa L

机构信息

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.

University of Utah, Salt Lake City, UT, USA.

出版信息

Gynecol Oncol Rep. 2024 May 11;53:101412. doi: 10.1016/j.gore.2024.101412. eCollection 2024 Jun.

DOI:10.1016/j.gore.2024.101412
PMID:38779189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11109349/
Abstract

Low grade serous ovarian cancers (LGSOC) in an advanced setting have limited systemic treatment options. In this paper we report a case of metastatic LGSOC harboring a BRAF mutation, treated with dabrafenib. We discuss the clinical, pathologic and molecular characteristics as well as surgical considerations and ongoing investigations in LGSOC.

摘要

晚期低度浆液性卵巢癌（LGSOC）的全身治疗选择有限。在本文中，我们报告了一例携带BRAF突变的转移性LGSOC病例，该病例接受了达拉非尼治疗。我们讨论了LGSOC的临床、病理和分子特征以及手术注意事项和正在进行的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/4a8a854cc6c4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/8cd8a57a229a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/2e59f48f6831/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/bc86e50567b6/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/4a8a854cc6c4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/8cd8a57a229a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/2e59f48f6831/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/bc86e50567b6/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633f/11109349/4a8a854cc6c4/gr4.jpg

相似文献

1
Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.复发性转移性低级别浆液性卵巢癌对BRAF抑制剂单药治疗的持久反应。
Gynecol Oncol Rep. 2024 May 11;53:101412. doi: 10.1016/j.gore.2024.101412. eCollection 2024 Jun.
2
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.在携带BRAF V600E突变的低级别浆液性卵巢癌中，达拉非尼和曲美替尼取得了令人印象深刻且持久的临床反应。
Gynecol Oncol Rep. 2022 Feb 23;40:100942. doi: 10.1016/j.gore.2022.100942. eCollection 2022 Apr.
3
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation.达拉非尼和曲美替尼治疗对一名接受过大量治疗的BRAF V600E突变低级别浆液性卵巢癌患者产生显著临床反应。
Gynecol Oncol Rep. 2018 Sep 10;26:41-44. doi: 10.1016/j.gore.2018.09.002. eCollection 2018 Nov.
4
Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.低级别浆液性卵巢癌和腹膜癌的进展。
Curr Oncol Rep. 2022 Nov;24(11):1549-1555. doi: 10.1007/s11912-022-01315-y. Epub 2022 Aug 13.
5
Investigating a clinically actionable mutation for monitoring low-grade serous ovarian cancer: A case report.探索一种可用于监测低级别浆液性卵巢癌的具有临床可操作性的突变：病例报告。
Case Rep Womens Health. 2022 Feb 6;34:e00395. doi: 10.1016/j.crwh.2022.e00395. eCollection 2022 Apr.
6
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.伴有BRAF V600E突变的低级别浆液性卵巢癌对维莫非尼的持续反应。
Invest New Drugs. 2015 Dec;33(6):1267-70. doi: 10.1007/s10637-015-0297-4. Epub 2015 Oct 21.
7
Complete Response With Trametinib in Advanced Low-Grade Serous Ovarian Carcinoma: A Case Report.曲美替尼治疗晚期低级别浆液性卵巢癌获得完全缓解：一例报告
Cureus. 2024 Feb 5;16(2):e53600. doi: 10.7759/cureus.53600. eCollection 2024 Feb.
8
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.联合 BRAF 和 MEK 抑制治疗 BRAF 突变型晚期低级别浆液性卵巢癌的完全缓解。
Ups J Med Sci. 2020 Nov;125(4):325-329. doi: 10.1080/03009734.2020.1826612. Epub 2020 Oct 10.
9
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.比美替尼（MEK162）用于对化疗和激素治疗耐药的复发性低级别浆液性卵巢癌。
Gynecol Oncol Rep. 2018 May 24;25:41-44. doi: 10.1016/j.gore.2018.05.011. eCollection 2018 Aug.
10
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction.辅助化疗在晚期低级别浆液性卵巢癌中的不确定获益及手术细胞减灭术的关键作用
J Clin Med. 2021 Dec 17;10(24):5927. doi: 10.3390/jcm10245927.

引用本文的文献

1
Unraveling alterations: molecular insights to circumvent therapeutic resistance across cancer types.揭示改变：跨越癌症类型规避治疗耐药性的分子见解。
Cancer Drug Resist. 2025 Mar 24;8:14. doi: 10.20517/cdr.2024.213. eCollection 2025.
2
A Rare Case of Ovarian Serous Borderline Tumor Recurrence with Muscle Metastasis.卵巢浆液性交界性肿瘤复发伴肌肉转移1例罕见病例
Am J Case Rep. 2025 Apr 3;26:e946680. doi: 10.12659/AJCR.946680.

本文引用的文献

1
Low-grade serous ovarian cancer: expert consensus report on the state of the science.低级别浆液性卵巢癌：科学现状的专家共识报告。
Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610.
2
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for V600E-Positive Adult and Pediatric Solid Tumors.拓展获益：达拉非尼联合曲美替尼作为组织学不可知论的 V600E 阳性成人和儿科实体瘤治疗药物。
Am Soc Clin Oncol Educ Book. 2023 May;43:e404770. doi: 10.1200/EDBK_404770.
3
Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
上皮性卵巢癌的分子特征和临床行为。
Cancer Lett. 2023 Feb 28;555:216057. doi: 10.1016/j.canlet.2023.216057. Epub 2023 Jan 7.
4
Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.低级别浆液性卵巢癌——一种治疗选择不断增加的罕见疾病。
Cancer Treat Rev. 2023 Jan;112:102497. doi: 10.1016/j.ctrv.2022.102497. Epub 2022 Dec 10.
5
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.在携带BRAF V600E突变的低级别浆液性卵巢癌中，达拉非尼和曲美替尼取得了令人印象深刻且持久的临床反应。
Gynecol Oncol Rep. 2022 Feb 23;40:100942. doi: 10.1016/j.gore.2022.100942. eCollection 2022 Apr.
6
Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.低级别浆液性卵巢癌中的突变与对BRAF抑制的反应
JCO Precis Oncol. 2018 Nov;2:1-14. doi: 10.1200/PO.17.00221.
7
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.曲美替尼对比标准治疗用于复发性低级别浆液性卵巢癌患者（GOG 281/LOGS）：一项国际性、随机、开放标签、多中心、2/3 期临床试验。
Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9.
8
The Evolution of Ovarian Carcinoma Subclassification.卵巢癌亚分类的演变
Cancers (Basel). 2022 Jan 14;14(2):416. doi: 10.3390/cancers14020416.
9
Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.复发性低级别浆液性卵巢癌的二次细胞减灭术：系统评价和荟萃分析。
Gynecol Oncol. 2022 Jan;164(1):212-220. doi: 10.1016/j.ygyno.2021.10.080. Epub 2021 Oct 28.
10
Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).低级别浆液性卵巢癌患者行细胞减灭术对生存的影响：土耳其妇科肿瘤学会（TRSGO-OvCa-001）的多中心研究。
J Surg Oncol. 2021 May;123(8):1801-1810. doi: 10.1002/jso.26450. Epub 2021 Mar 3.